AI assistant
Vaxcyte, Inc. — Director's Dealing 2024
Apr 3, 2024
31100_dirs_2024-04-03_aa0feb43-f409-4cde-bcd7-b355a59a57b5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-04-01
Reporting Person: Eydelman Mikhail (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-01 | Common Stock | M | 1667 | $21.41 | Acquired | 32264 | Direct |
| 2024-04-01 | Common Stock | S | 1397 | $66.594 | Disposed | 30867 | Direct |
| 2024-04-01 | Common Stock | S | 270 | $67.416 | Disposed | 30597 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-01 | Stock Option (right to buy) | $21.41 | M | 1667 | Disposed | 2032-05-08 | Common Stock (1667) | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $66.185 to $67.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $67.37 to $68.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.